Health Press Release – Weekly Newsletter for January 3-10, 2011

AMP’s SIVAC Initiative Supports the Creation of a Mongolian National Immunization Technical Advisory Group (NITAG)

PARIS, January 4, 2011 – The inaugural meeting of the Mongolian National Immunization Technical
Advisory Group (NITAG) was held at the Ministry of Health in Ulaanbaatar on
December 6, 2010.

The NITAG is the first of its kind in Mongolia and was established based
on recommendations from the World Health Organization (WHO). The committee's
role …. Source  : Gaea News Network.

Santaris Pharma A/S Announces Expanded Worldwide Strategic Alliance With Pfizer Inc. Directed to Development of RNA-targeted Medicines

Pfizer to make payment of $14 million for access to Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform to develop RNA-targeted drugs

HOERSHOLM, Denmark and SAN DIEGO, January 4, 2011 – Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused
on the research and development of mRNA and microRNA targeted therapies, and
Pfizer Inc. (NYSE: PFE), today …. Original article  : Santaris Pharma A/S Announces Expanded Worldwide Strategic Alliance With Pfizer Inc. Directed to Development of RNA-targeted Medicines.

Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors

ROCHESTER, New York, January 4, 2011 – Vaccinex, Inc. announced today that it has received clearance from FDA
and will initiate a Phase 1 clinical trial to assess the safety,
tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody
candidate VX15/2503 in cancer patients with advanced solid tumors.

(Logo: photos.prnewswire.com/prnh/20101101/NY92716LOGO )
VX15/2503 is … Read more »»».

‘Diabetes’ Is Fifth Disability Intensive Course Introduced to College of Direct Support (CDS) Curriculum

ATLANTA, January 4, 2011 – The College of Direct Support (CDS), an internet-based college
for Direct Support Professionals (DSPs) and managed in partnership by
Elsevier I MC Strategies and the University of Minnesota's Research and
Training Center, has introduced its newest Disability Intensive Course (DIC)
into the CDS Curriculum – Diabetes

This is the fifth … Original source on Gaea Times at : 'Diabetes' Is Fifth Disability Intensive Course Introduced to College of Direct Support (CDS) Curriculum.

ReproCELL to Enter Collaborative R&D on Human iPS Cell Derived Hepatocytes

YOKOHAMA, Japan, January 4, 2011 – ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today
that the company will enter a collaborative R&D agreement with the National
Institute of Biomedical Innovation (NIBIO; Director General: Koichi
Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human
iPS (induced pluripotent stem) cells used for an effective in-vitro drug
screening for hepatic …. Source  : Gaea News Network.

Mike Romanos Appointed as CEO of Crescendo Biologics

CAMBRIDGE, England, January 5, 2011 – Crescendo Biologics Limited (Crescendo) today announces the
appointment of Mike Romanos as Chief Executive Officer. Dr Romanos has been
Chief Scientific Officer of the company since May 2009 and has led the
formation of the company and the development of its proprietary antibody
fragment technologies.

During this time, the …. Source article on Gaea Times at  : Mike Romanos Appointed as CEO of Crescendo Biologics.

Elsevier is the New Publisher of Value in Health, the Official Journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

OXFORD, England, January 5, 2011 – Elsevier, the world's leading publisher of scientific, technical and
medical information, announced today that it has become the new publisher of
the International Society for Pharmacoeconomics and Outcomes Research's
(ISPOR) journal Value in Health.

Value in Health (
www.elsevier.com/wps/find/journaldescription.authors/724501/descriptio
n#description) is a multidisciplinary peer-reviewed journal reporting on
outcomes research evaluations of … Read : Elsevier is the New Publisher of Value in Health, the Official Journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

7th NIZO Dairy Conference to Focus on Flavour and Texture, Innovations in Dairy

Conference to be Held on 21-23 September 2011, in Arnhem, the Netherlands
AMSTERDAM, January 5, 2011 – NIZO food research, in association with Elsevier, the leading publisher
of scientific, technical and medical information products and services,
announces the 7th NIZO Dairy conference, to be held on 21-23 September 2011,
in Arnhem, The Netherlands.

The conference …. Source  : Gaea News Network.

SuperNova Diagnostics(R) to Present at Biotech Showcase(TM) 2011 During J.P. Morgan Healthcare Conference January 10-13

WASHINGTON, LONDON and HONG KONG, January 5, 2011 – SuperNova Diagnostics(R), Inc., a privately-held global diagnostics
company for human and non-human health applications, announced today that
Neil J. Campbell, president and CEO, will present at Biotech Showcase 2011 in
conjunction with the J.P. Morgan Healthcare Conference in San Francisco, CA.

Mr. Campbell's presentation will … Read the original article on Gaea Times at : SuperNova Diagnostics(R) to Present at Biotech Showcase(TM) 2011 During J.P. Morgan Healthcare Conference January 10-13.

Cell Biosciences Launches New Platform for Multiplex Western Blot Detection

SANTA CLARA, California, January 5, 2011 – Cell Biosciences, Inc., a provider of innovative protein analysis tools
to life science researchers, today announced the launch of the latest
addition to their premier line of next-generation imaging products, the
FluorChem(R) M MultiFluor system. This new platform combines highly-sensitive
quantitative detection of multicolor fluorescent Western blots with key
ease-of-use features aimed … Read : Cell Biosciences Launches New Platform for Multiplex Western Blot Detection.

Findings Published in Journal of Pharmacology and Experimental Therapeutics Demonstrate Potential for Amira Pharmaceuticals’ LPA1 Receptor Antagonist as an Anti-Fibrotic Agent

SAN DIEGO, January 5, 2011 – Amira Pharmaceuticals, Inc. announced today the publication of its
findings in the Journal of Pharmacology and Experimental Therapeutics (JPET)
which describes the biologic effects and the characterization of AM095, a
lysophosphatidic acid (LPA) receptor 1 antagonist, in various in vitro and
in vivo models of fibrotic disease.

"Activation of … Read more >>>.

Manchester Dental Education Centre Chooses Mediasite for Lecture Capture, Event Webcasting

Mediasite lecture capture technology chosen for creating modern education center

MADISON, Wisconsin, January 5, 2011 – Manchester Dental Education Centre (MANDEC) has expanded its audience
reach by adding Mediasite by Sonic Foundry, Inc. (Nasdaq: SOFO), the
recognized market leader for rich media webcasting, lecture capture and
knowledge management, to its classroom technology offering.
"The Mediasite …. Original source  : Manchester Dental Education Centre Chooses Mediasite for Lecture Capture, Event Webcasting.

Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) Now Available at ReportsnReports

DALLAS, January 6, 2011 – ReportsnReports announces it will carry Advanced Drug Delivery Markets
(Liposomes, Polymers and Monoclonal Antibodies) Research Report in its store.
Drug delivery is evolving at a rapid rate with new drug product formulations
being discovered frequently. Advanced drug delivery deals with developing
solutions for new entities in therapeutic pharmacology such as protein and
peptides and …. Source article  : Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) Now Available at ReportsnReports.

Spirogen Ltd. Announces a Research Collaboration and License Agreement With Genentech for the Discovery and Development of Antibody Drug Conjugates

LONDON, January 6, 2011 – Spirogen Ltd. ("Spirogen") a leading oncology-focused company developing
DNA sequence targeted agents, announced a multi-year research collaboration
and license agreement with Genentech, a member of the Roche Group (SIX: RO,
ROG; OTCQX:RHHBY).

The two companies will collaborate on the discovery and development of
antibody drug conjugates (ADCs) as potential anticancer …. Read the original article  : Spirogen Ltd. Announces a Research Collaboration and License Agreement With Genentech for the Discovery and Development of Antibody Drug Conjugates.

Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity

Company to begin distribution discussions at J.P. Morgan Conference
PALO ALTO, California, January 6, 2011 – Viveve, Inc., a development stage women's health company, announced today
that it has received the European CE (Conformite Europeenne) mark for the use
of its Viveve System for the non-surgical treatment of laxity of the vaginal
introitus (opening), after childbirth, to improve … Read : Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity.

Vapotherm, Inc. Announces CE Mark Approval for Flowrest(R) Homecare Device

STEVENSVILLE, Maryland, January 6, 2011 – Vapotherm, the global leader in High Flow Therapy products, announced
receiving CE marking for Flowrest(R), a device designed for homecare and
other low acuity environments.

The Flowrest(R) device delivers warmed humidified high-flow breathing
gases for treating spontaneously breathing patients via nasal cannula.
Flowrest(R) is designed for ease of use … Read more : Vapotherm, Inc. Announces CE Mark Approval for Flowrest(R) Homecare Device.

College of Emergency Medicine Prescribes DediPower and Deeson Online To Deliver New eLearning Platform

Exciting Interactive Training Site Brings Doctors Greater Convenience, Faster Access and Richer Content

READING, England, January 6, 2011 – The prestigious College of Emergency Medicine (CEM) is advancing medical
training for its 2,900 members with the introduction of a new web-based
eLearning platform built by digital specialists Deeson Online and hosted by
DediPower Managed Hosting.
…. Read the original article  : College of Emergency Medicine Prescribes DediPower and Deeson Online To Deliver New eLearning Platform.

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis (DVT) and Prevention of Recurrent DVT and Pulmonary Embolism (PE)

Submission in Stroke Prevention in Patients With Non-valvular Atrial Fibrillation (AF) Based on Positive Results of ROCKET AF Trial in More Than 14,000 Patients

NEWBURY, England, January 6, 2011 – Bayer has submitted an application for marketing authorisation to the
European Medicines Agency (EMA) for the oral anticoagulant rivaroxaban in
stroke prevention in patients with non-valvular atrial …. Source  : Gaea News Network.

Novo Nordisk’s Innovative Needle – NovoTwist(R) – Wins GOOD DESIGN(TM) Award

COPENHAGEN, Denmark, January 6, 2011 – Novo Nordisk has been awarded the 2010 GOOD DESIGN(TM) Award[1] for
NovoTwist(R), the innovative needle designed for use with the Novo
Nordisk insulin delivery device FlexPen(R) and Victoza(R) (liraglutide) Pen.

The GOOD DESIGN(TM) Award[1] is judged based on design innovation beyond
what is considered ordinary, and on whether … Original article on : Novo Nordisk's Innovative Needle – NovoTwist(R) – Wins GOOD DESIGN(TM) Award.

Santander Corporate Banking Supports Extension of Arrowsmith Lodge Care Home

LONDON, January 6, 2011 – Preston-based care home Arrowsmith Lodge will be able to offer a further
13 beds for the elderly and dementia patients with the help of a new
commercial mortgage from Santander Corporate Bank. Experts in personal
banking services, from home insurance (
products.santander.co.uk/insurance/homeinsurance.html) to travel
insurance, Santander's corporate arm successfully extends to commercial
residential services.

… Read this article on Gaea Times at : Santander Corporate Banking Supports Extension of Arrowsmith Lodge Care Home.